Healthcare resource utilization and economic burden of multiple sclerosis in Chinese patients: results from a real-world survey.

ABSTRACT: Multiple sclerosis (MS) is uncommon in China and the standard of care is underdeveloped, with limited utilization of disease-modifying treatment (DMT). An understanding of real-world disease burden (including direct medical, non-medical, and indirect costs, such as loss of productivity), is currently lacking in this population. To investigate the overall burden of managing patients with MS in China, a cross-sectional survey of physicians and their consulting patients with MS was conducted in 2021. Physicians provided information on healthcare resource utilization (HCRU; consultations, hospitalizations, tests, medication) and associated costs. Patients provided data on changes in their life, productivity, and impairment of daily activities due to MS. Results were stratified by disease sever

SUBMITTER: Sun C 

PROVIDER: S-EPMC11219786 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature